Evidence supports the efficacy of testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD) but clinicians still have questions about whether the disorder warrants treatment and how therapy should be delivered, according to Melbourne endocrinologist Susan Davis.
Professor Davis, who is Professor of Women’s Health at Monash Medical School, argued in a review in Clinical Endocrinology that HSDD had negative effects on mental health, vitality, social function and bodily pain.
“Loss of sexual desire for many women is a significant cause of loss of personal well-being, personal distress and relationship disharmony,” she said.
Existing clinical guidelines on testosterone therapy for women did not reflect the consistent findings from a number of recent large studies.
They showed that the...
This site is intended for Registered Medical Practitioners.
To make the most of Endocrinology Update, you need to be logged in.